WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017172990) ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/172990    International Application No.:    PCT/US2017/024853
Publication Date: 05.10.2017 International Filing Date: 29.03.2017
IPC:
C07K 16/30 (2006.01), C07K 16/28 (2006.01), C12N 5/16 (2006.01), G01N 33/574 (2006.01), A61K 47/50 (2017.01), A61K 49/00 (2006.01), A61K 39/00 (2006.01)
Applicants: OBI PHARMA, INC.; Room W1907, 19f 3 Yuan-Qu Street, Nankang District Taipei City, 11503 (TW).
YU, Cheng-Der Tony [US/--]; (TW) (MW only)
Inventors: YU, Cheng-Der Tony; (TW).
LAI, Jiann-Shiun; (TW).
CHEN, I-Ju; (TW).
LIN, Chiu-Chun; (TW)
Agent: NORTON, Vicki G.; (US)
Priority Data:
62/314,841 29.03.2016 US
Title (EN) ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
(FR) ANTICORPS, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS
Abstract: front page image
(EN)Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
(FR)L'invention concerne une composition pharmaceutique comprenant des anticorps ou des fragments de liaison à l'antigène correspondants qui se lient à l'antigène embryonnaire spécifique de stade (SSEA-4), ainsi que des procédés d'utilisation correspondants. Les procédés d'utilisation comprennent, sans caractère limitatif, des traitements et des diagnostics du cancer. Les anticorps selon l'invention peuvent se lier à certaines surfaces de cellules cancéreuses. Les cibles données à titre d'exemple des anticorps décrits peuvent comprendre des carcinomes tels que le cancer du sein, le cancer du poumon, le cancer de l'oesophage, le cancer rectal, le cancer des voies biliaires, le cancer du foie, le cancer buccal, le cancer de l'estomac, le cancer du côlon, le cancer du nasopharynx, le cancer du rein, le cancer de la prostate, le cancer de l'ovaire, le cancer du col de l'utérus, le cancer de l'endomètre, le cancer du pancréas, le cancer du testicule, le cancer de la vessie, le cancer de la tête et du cou, le cancer de la bouche, le cancer neuroendocrinien, le cancer des glandes surrénales, le cancer de la thyroïde, le cancer des os, le cancer de la peau, le carcinome basocellulaire, le carcinome épidermoïde, le mélanome et/ou la tumeur cérébrale.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)